New Gene-Silencing shot aims to tame bad cholesterol
NCT ID NCT07428473
Summary
This is a first-in-human study to test the safety of a new investigational drug called STX-1150, designed to lower 'bad' LDL cholesterol. It will enroll up to 64 people with high cholesterol in Australia and New Zealand. The treatment uses a one-time infusion to temporarily 'silence' a liver gene that controls cholesterol levels, with researchers monitoring participants for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED LDL-C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash Health/ Victorian Heart Hospital (VHH)
Clayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.